NCT03924466 2024-02-16
VUBAR
Universitair Ziekenhuis Brussel
Phase 2 Unknown
Clinical Trials
20 trialsNCT05823246 2023-05-26
Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT04543110 2023-03-23
RADIANT
Ottawa Hospital Research Institute
Phase 2 Unknown
NCT05775874 2023-03-20
A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC
Abbisko Therapeutics Co, Ltd
Phase 2 Unknown
NCT04730219 2022-11-30
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT03827837 2022-07-01
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT03062059 2022-04-14
The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence
National Cancer Center, Korea
Phase 2 Unknown
NCT05318339 2022-04-08
A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma
ChineseAMS
Phase 2 Unknown
NCT02535650 2022-03-08
Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma
Samsung Medical Center
Phase 2 Unknown
NCT04047693 2022-02-18
Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma
Pusan National University Yangsan Hospital
Phase 2 Unknown
NCT04839510 2021-12-14
A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer
Shanghai Miracogen Inc.
Phase 2 Unknown
NCT03219775 2021-11-03
TITAN-TCC
AIO-Studien-gGmbH
Phase 2 Unknown
NCT05030077 2021-09-01
Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma
Tianjin Medical University Second Hospital
Phase 2 Unknown
NCT04383067 2021-02-11
A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients
Sheba Medical Center
Phase 2 Unknown
NCT04211012 2020-11-13
A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown
NCT03745911 2018-11-19
Paclitaxel and TAK-228 in Urothelial Carcinoma
Associació per a la Recerca Oncologica, Spain
Phase 2 Unknown
NCT03209206 2017-12-22
The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence
Seoul National University Hospital
Phase 2 Unknown
NCT02278978 2015-05-12
BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma
National Taiwan University Hospital
Phase 2 Unknown
NCT01215877 2012-07-11
Tesetaxel for Previously Treated Patients With Bladder Cancer
Genta Incorporated
Phase 2 Unknown